VB Spine Expands FDA Clearances for Vitoss Bone Graft and Interbody Cages
Event summary
- FDA granted two 510(k) clearances to VB Spine on July 29, 2026, expanding indications for Vitoss® Bone Graft Substitute and interbody cages.
- Clearances allow Vitoss® use in intervertebral disc space with interbody cages, including pediatric and tumor-related cases.
- VB Spine's interbody cages can now be used with bone void fillers cleared for spinal fusion procedures.
- Vitoss is licensed from Stryker Corporation.
The big picture
VB Spine's expanded FDA clearances position it to challenge traditional autograft reliance in spine surgery, aligning with broader industry shifts toward synthetic alternatives. The move follows recent acquisitions and product launches, signaling a strategic push into advanced spinal care solutions. With Vitoss® now cleared for complex cases like pediatric and tumor-related procedures, VB Spine may gain market share in high-growth segments.
What we're watching
- Market Adoption
- How quickly surgeons will integrate Vitoss® and interbody cages into anterior column defect treatments.
- Competitive Response
- Whether competitors will accelerate development of similar synthetic bone graft solutions.
- Regulatory Strategy
- The pace at which VB Spine expands indications for other products in its biologics portfolio.
Related topics